Table 1.

Characteristics of HCV-infected injection drug users, San Francisco Bay area, 1998-2000

	HCV Antibody (n=2092)		HCV Viremia (n=1701)		Viral Genotype Determined (n=1524)		IL28BGenotype Determined (n=882)
Characteristic	Median	IQRa	Median	IQR	Median	IQR	Median	IQR
Age at enrollment	45	40-50	46	40-50	46	40-50	44	39-49
Years of injection drug use	25	17-31	26	18-32	26	18-32	25	18-31
Age at first injection drug use	18	16-24	18	16-24	18	16-24	18	16-22
	No.	%	No.	%	No.	%	No.	%
Genderb
Male	1461	70.9	1222	72.4	1104	73.1	615	69.7
Female	600	29.1	465	27.6	407	26.9	267	30.3
Race
White	759	36.3	577	33.9	522	34.3	391	44.3
African American	1078	51.5	951	55.9	861	56.5	347	39.3
Latino	167	8.0	115	6.8	92	6.0	88	10.0
Asian or Pacific Islander	28	1.3	19	1.1	15	1.0	18	2.0
American Indian	58	2.8	37	2.2	32	2.1	36	4.1
Other	2	0.1	2	0.1	2	0.1	2	0.2
Hepatitis B virus infection
Acute	18	0.9	7	0.4	7	0.5	5	0.6
Chronic	53	2.5	29	1.7	26	1.7	28	3.2
Resolved	1641	78.4	1348	79.2	1197	78.5	680	77.1
Vaccinated	78	3.7	70	4.1	65	4.3	38	4.3
Uninfected and unvaccinated	302	14.4	247	14.5	229	15.0	131	14.9
HIV-1 infection	262	12.5	237	13.9	211	13.8	107	12.1

^aIQR: interquartile range (25^th percentile-75^th percentile)

^bMissing data: gender, 31; HIV-1 infection, 3